首页> 外文OA文献 >Human Umbilical Cord Mesenchymal Stem Cells Ameliorate Hepatic Stellate Cell Activation and Liver Fibrosis by Upregulating MicroRNA-455-3p through Suppression of p21-Activated Kinase-2
【2h】

Human Umbilical Cord Mesenchymal Stem Cells Ameliorate Hepatic Stellate Cell Activation and Liver Fibrosis by Upregulating MicroRNA-455-3p through Suppression of p21-Activated Kinase-2

机译:通过抑制P21活化激酶-2,通过抑制MicroRNA-455-3P来改善肝脏星形细胞活化和肝纤维化的人的脐带间充质干细胞。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mesenchymal stem cells (MSCs) were shown to have potential therapeutic effects for treatment of liver fibrosis, and dysregulated expression of microRNAs (miRNAs) played a pivotal role in the pathogenesis of liver fibrosis by regulating their downstream target genes. However, the mechanism by which MSCs affect the progression of liver fibrosis by regulating miRNA expression remains unclear. Here, we investigated whether human umbilical cord MSCs (HUC-MSCs) attenuated hepatic fibrosis by regulating miR-455-3p and its target gene. Significantly upregulated miRNA (miR-455-3p) was screened out by GEO datasets analysis and coculture HUC-MSCs with hepatic stellate cell (HSC) LX-2 cells. p21-activated kinase-2 (PAK2) was forecasted to be the target gene of miR-455-3p by bioinformatics analyses and confirmed by luciferase reporter assay. HUC-MSCs were transplanted into mice with carbon tetrachloride- (CCl4-) induced liver fibrosis, the result showed that HUC-MSC transplantation significantly ameliorated the severity of CCl4-induced liver fibrosis, attenuated collagen deposition, improved liver function by reducing the expression of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum, upregulated miR-455-3p, and suppressed PAK2 expression of liver tissue in mice. Taken together, our study suggests that HUC-MSCs inhibit the activation of HSCs and mouse CCl4-induced liver fibrosis by upregulation of miR-455-3p through targeting PAK2.
机译:间充质干细胞(MSCs)显示用于治疗肝纤维化的潜在治疗效果,并且通过调节其下游靶基因来调节肝纤维化的发病机制中的微血管(miRNA)的失调表达在肝纤维化的发病机制中发挥了枢转作用。然而,通过调节miRNA表达,MSCs影响肝纤维化进展的机制仍不清楚。在这里,我们研究了人类脐带MSCs(HUC-MSCs)是否通过调节miR-455-3p及其靶基因来减毒肝纤维化。通过Geo DataSets分析和与肝星状细胞(HSC)LX-2细胞的Geo DataSets分析和共培养HUC-MSCs筛分显着上调的miRNA(miR-455-3p)。预计将P21-活化的激酶-2(PAK2)被生物信息学分析和证实的生物信息学分析并确认是MIR-455-3P的靶基因,并通过荧光素酶报告分析进行。 HUC-MSCs被移植到具有碳四氯化碳 - (CCL4-)诱导的肝纤维化的小鼠中,结果表明,HUC-MSC移植显着改善了CCL4诱导的肝纤维化的严重程度,减弱了胶原沉积,通过减少表达来改善肝功能丙氨酸氨基转移酶(ALT)和天冬氨酸氨基转移酶(AST)在血清中,上调miR-455-3p,抑制小鼠肝组织的PAK2表达。我们的研究表明,HUC-MSCs通过靶向PAK2来抑制HSC-455-3P的UR-455-3P的HSC和小鼠CCL4诱导的肝纤维化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号